Actively Recruiting
Platform Study Evaluating ABBV-142 and Placebo in Adults With Idiopathic Pulmonary Fibrosis
Led by AbbVie · Updated on 2026-09-03
165
Participants Needed
57
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Idiopathic Pulmonary Fibrosis IPF is a rare, chronic lung disease that causes scarring of lung tissue, resulting in shortness of breath and reduced lung function. This platform study evaluates various treatments for IPF, including the investigational drug ABBV-142. The study aims to assess the safety, tolerability, and effectiveness of these treatments in adults with IPF using a master protocol that allows adding or closing substudies over time. Participants will be randomly assigned to receive either ABBV-142 or a matching placebo in a double-blind manner for 52 weeks during the initial treatment phase. Those who qualify may then receive ABBV-142 for an additional 52 weeks in an open-label extension. This design helps compare the investigational drug with placebo and further monitors participants over an extended period. Throughout the study, participants will attend regular visits at hospitals or clinics where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted. Researchers will measure lung function changes, adverse events, and quality of life impacts. After treatment, participants will be followed for 120 days to monitor their health and study outcomes.
CONDITIONS
Brief Title
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here